sessed for 4 MM patients using quantitative patient-specific with multiple myeloma (MM) are here shown to include 23% in situ RT-PCR. For 9 of 11 myeloma patients tested, CD34 10 The relationship of circulating clonotypic B cells to the malignant process is as yet undefined, pating in homing or anchoring in a BM stromal environment. 24, 25 This report shows that CD34, which is expressed but the presence of a DNA aneuploid subset 5, 11, 12 and N-ras mutation 13 suggests at least a subset of these cells may be on normal hematopoietic stem cells, 26,27 is also expressed at relatively high density on 3% to 37% of peripheral blood malignant. Populations of MM blood B cells may also include members of the original antigen-specific B-cell clone mononuclear cells (PBMC) in myeloma, is coexpressed with CD19 on 50% to 60% of monoclonal blood B cells in myfrom which the malignant transformant arose. of autologous myeloma plasma cells in 9 of 11 MM patients Submitted May 28, 1996; accepted October 10, 1996. tested, indicating a clonal relationship.
" MM blood B cells were amfrom blood and thus spread of myeloma through the skeletal plified by nested PCR using consensus primers followed by system. Southern blotting with allele-specific oligonucleotides for 7 ᭧ 1997 by The American Society of Hematology. MM patients, and clonotypic IgH mRNA expression was as-M surface Ig. 5, 7, 15 They have the adhesive and motile properties required for a potentially invasive subset able to traffic to ULTIPLE MYELOMA (MM) is characterized by extensive infiltration of the bone marrow (BM) by monoclonal plasma cells.
1 The self-renewing stem cell in distant BM sites. [14] [15] [16] [17] They persist in blood despite chemotherapy 7 and express functional P-glycoprotein 170, 12, 18, 19 myeloma is likely to be a B-lineage cell less mature than the end-stage plasma cells in the BM. [2] [3] [4] [5] [6] [7] Recent work has shown by others to modulate the response of myeloma patients to chemotherapy. 20, 21 conclusively shown the presence in myeloma of monoclonal blood B cells (MM blood B cells) 8, 9 with an IgH rearrangeNo matter where myeloma originates, spread of the malignancy from the place of origin to distant BM sites must be ment identical to that of autologous malignant plasma cells in myeloma. 7 Sequencing of the IgH VDJ DNA from single through the blood. Traffic from blood to BM requires binding to endothelium and extravasation. CD34 is a sialomucin, 22 sorted B cells of MM patients indicates that the majority have an IgH rearrangement identical to that of autologous which serves as a ligand for L-selectin, 23 perhaps binding to an as yet unidentified endothelial or BM ligand and particimyeloma plasma cells. 10 The relationship of circulating clonotypic B cells to the malignant process is as yet undefined, pating in homing or anchoring in a BM stromal environment. 24, 25 This report shows that CD34, which is expressed but the presence of a DNA aneuploid subset 5, 11, 12 and N-ras mutation 13 suggests at least a subset of these cells may be on normal hematopoietic stem cells, 26, 27 is also expressed at relatively high density on 3% to 37% of peripheral blood malignant. Populations of MM blood B cells may also include members of the original antigen-specific B-cell clone mononuclear cells (PBMC) in myeloma, is coexpressed with CD19 on 50% to 60% of monoclonal blood B cells in myfrom which the malignant transformant arose. 8 The contribution of circulating B cells to the malignant eloma, and is absent from most myeloma plasma cells in the BM 28 as well as from most normal B cells. In this report we process in MM is not fully defined. MM blood B cells express mRNA encoding Ig light chain, 14 In situ reverse transcriptase-polymerase chain reaction (RTplasma cells were purified by sorting for cells that coexpressed the plasma cell marker PCA-1 and a high density of cytoplasmic Ig PCR). In situ RT-PCR 31 was used to quantitate the proportion of sorted PBMC expressing mRNA encoding CD34, IgH, CD19, or (cIg). IgH VDJ PCR used 1,000 cells from each subset as previously described, using consensus primers in nested PCR, 7 followed by histone. PBMC from MM patients were stained in double direct immunofluorescence with MoAbs CD19-FITC and CD34-PE, and electophoresis on a 4% Nusieve GTG agarose gel (FMC Bioproducts, Rockland, ME). These Ig fingerprints were transferred to nyfixed in 10% formalin/PBS overnight. Using the ELITE Autoclone (Coulter), total CD34
/ PBMC or CD34 / 19 / B cells were sorted at lon filters by Southern blotting and hybridized with end-labeled ASO probes designed using the patient-specific IgH-CDR3 sequence of 10,000 cells per well into a flat-bottom 96-well microtiter tray. Rapid processing before the fixation step was essential to preserve mRNA.
purified BM plasma cells from the same patient as detailed previously. 7 The presence of ASO sequences in each subset was also Samples were placed in three spots, at 10,000 cells per spot, on In Situ PCR glass slides (Perkin Elmer, Mississagua, Ontario, Canada) confirmed using ASO-PCR. 7 N-ras DNA was amplified as a positive control to confirm that the DNA in each sample was intact. For and air dried. Cells were permeabilized using 2 mg pepsin (Boehringer Mannheim, Laval, Quebec, Canada) per milliliter of 0.01N sequencing and synthesis of ASO probes, the CDR3 PCR products were amplified as above, purified from an agarose gel using Promega HCl. The time of pepsin digestion was carefully optimized. Pepsin was inactivated by a 1-minute wash in diethyl pyrocarbonate Magic PCR Preps (Promega, Madison, WI), and the nucleotide sequence determined using end-labeled oligonucleotides FR2 and JH2 (DEPC)-treated water followed by a 1-minute wash in 100% ethanol. Digestion with 1,000 U/mL of DNAseI (RNAse-free) ( ing within the small lymphocyte gates, 79% expressed CD34
The results from these two methods were not significantly different. Samples were run on either the FACSort or ELITE, with comparable mRNA, and 51% expressed CD19 mRNA ( was also confirmed by amplification of CD34 mRNA from of PBMC were CD34 med/hi (mean Å 23% {2%), compared bulk mRNA isolated from purified myeloma blood B cells with less than 1% in normal adult blood, 1% to 4% in cord (not shown). In contrast, only 1% to 2% of B cells from 5 blood, 1% to 5% in G-CSF-mobilized blood, and 3% to 5% normal donors stained with any members of the CD34 MoAb in adult BM (Table 1 and Fig 1) . A comparable number of CD34 / MM or normal PBMC/BMC were detected using panel ( 
19
/ B cells to the malignant clone in MM, 
" sorts 98% Ô 0.7% were within the selected sort window and had 0.26% Ô 0.3% cells from the other sort window; for CD34 Ï
" sorts 97% Ô 0.5% were within the selected sort window and 0.5% Ô 0.6% were from the other sort window (values are mean ÔSD).
of clonotypic sequences can be compared between samples these rearrangements hybridized with the appropriate ASO probe is shown in the lower half of each panel. The ASO and patients. PBMC from MM patients or normal donors were stained with CD19 MoAb and sorted for positive cells. On reanalysis ú96% of sorted cells were positive for CD19 staining. For some samples very few slides were available for this analysis. T cells from MM patients had 0% to 8% of cells that were weakly positive for CD34 mRNA, and none that had an accumulation of colored product comparable to that seen for B cells (not shown), and lacked IgH or CD19 mRNA. 
/ B cells in trolling for the quality of DNA, and the PCR amplification. PCR false positives are also controlled for since all of the MM PBMC that were expressing clonotypic IgH mRNA, in situ RT-PCR using patient-specific primers (CDR3 and different patient samples are amplified identically, so that any PCR contaminant could not be patient-specific. CDR2 or FR2) was used (Table 7 and Fig 3) . Because in situ RT-PCR amplification detects as few as 1 to 10 copies The specificity of the amplification was confirmed by the lack of amplification of IgH rearrangements from sorted T of IgH VDJ mRNA 32,33 in individual cells with a colorimetric sandwich assay, this method is considerably more sensitive cells from myeloma patients, from fibroblasts (panels E through G), or from water (data not shown). The specificity than the bulk PCR followed by ASO Southern blotting described above. CD34
/

19
/ MM B cells were sorted, placed of the ASO blotting was confirmed by the absence of hybridization to any of the bands amplified from polyclonal PBMC on slides, and their mRNA amplified using patient-specific primers (Table 6) . For all 4 patients, the IgH VDJ sequences B cells from normal donors (panels B through G). Previous work has established that ASO probes hybridize only to defined as patient-specific were confirmed to be clonotypic by their expression in 80% or more of individual autologous bands amplified from the appropriate myeloma patient.
7
For patients A and B, although IgH CDR3 sequences were BM plasma cells, but not from plasma cells of unrelated MM patients. As a negative control in the in situ RT-PCR, amplified for all subsets, only those amplified from the CD34 / subset of blood B cells hybridized with the ASO patient-specific primers did not amplify detectable product in any of the sorted B cells from unrelated MM patients or probes defined by the IgH CDR3 rearrangement from autologous BM plasma cells. For patients C through E, hybridizanormal donors (Table 7) . For 4 of 4 MM patients tested, patient-specific primers tion with ASO probes was seen for rearrangements amplified from both CD34 / and CD34 0 B cells, and in relative terms, amplified a clonotypic product in 74% to 94% of individual CD34 / 19 / B cells, confirming that for all MM patients tested a greater proportion of CD34 / B cells were clonotypic for C and D, while for E, CD34 0 B cells appeared to have nearly all cells in this PBMC subset are clonally related to the malignant BM plasma cells in MM (Table 7) . Figure 3 , the greater proportion of the ASO sequence. Patient E was analyzed at three different time points over a 10-month pebottom row, shows representative patient-specific in situ RT-PCR for the appropriate MM patient where nearly all cells riod and the expression of ASO sequences in both CD34 / and CD34 0 subsets was consistently seen, as was the relaare positive, and for B cells from a normal donor, which are negative (Fig 3) . Of the 4 patients shown, 1 was untreated tively greater hybridization in the CD34 0 subset. For patients F and G, the ASO sequences were mainly detected among (no. 2), 1 had recently undergone a transition from monoclonal gammopathy of undetermined significance (MGUS) the CD34 0 B cells; patient F was newly diagnosed and patient G was 2 months postdiagnosis. Patients A through E, to MM and initiated chemotherapy (no. 8), 1 had completed chemotherapy (no. 1), and 1 was in relapse (no. 9). all of whom had clonotypic sequences among the CD34 / Bcell subset, were postchemotherapy, and all except A were by the adhesive properties of CD34 [22] [23] [24] that have been confirmed in CD34 transgenic mice, 25 as well as its role in
